Xu, Yanjun

Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial

Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., et al. (2021) · Journal of Thoracic Oncology

Lung Cancer Research StudiesLung Cancer Treatments and Mutations

Cited by 135

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

Chen, K., Yu, X., Wang, H., Huang, Z., Xu, Y., Gong, L., & Fan, Y. (2017) · Cancer Chemotherapy and Pharmacology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 31